Webdisclosure.fr

Search

UCB (EBR:UCB) UCB Media Room: Acquisition of own shares

Directive transparence : information réglementée

05/04/2024 20:01
https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC= rjYrJUHPDVbu1NKaBE-3D6CBy_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2= FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN= n-2B6FohpNoV33vsNKk-2BltEHyhBHdHmurNCHCJ1LdPOMT5P5bitk3PhfOggWSIfr06nTUA3mP= MJj6Wb68XFoe1TOHwxCBf2LMmO-2F8TCmbnB-2BU6WJdFyvTaxq-2F-2Fn-2BaIrK1wz6V1dqrk= wONQaqEb8Wa1pasrWwYPem5ag2LBUlmNcYEzVnzsXl5nI2OGgFVqxNARfSpe5UUR8qxh0Y9tKds= uZcGfPKYH9FoYfa8R771tnEh8n-2F2yz0h16ms-3D ** Acquisition of own shares ------------------------------------------------------------ Brussels (Belgium), 05 April 2024 =E2=80=93 20:00 (CEST) =E2=80=93 Regulate= d information=C2=A0 Acquisition of own shares In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB= =E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose= s certain information in relation to its Share Repurchase Program 2024.=C2= =A0 Under this program, UCB has requested a financial intermediary to repurchas= e up to 1,300,000 UCB shares on its behalf under the terms of a discretiona= ry mandate agreement with initial validity until 30 June 2024, effective as= from 02 April 2024, to cover current and future obligations under UCB's Lo= ng Term Incentive Plans for its personnel. In the framework of this Share Repurchase Program 2024, UCB repurchased 94,= 467 UCB shares on Euronext Brussels in the period from 02 April 2024 up to = and including 04 April 2024, as follows:=C2=A0 https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepadzxDFtX8-2FEDs9gF-2F9WS5uq3DSmMCyjGDRjVjnAok1xbMEa= FEnxpXHhEeRv5RnHxVTnLMKkfiqGcJ2DmazeLkTf9Kr_2dCLUNbuBjhX746-2FvM63L9Hyn3KnT= FGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIx= s8cV3s33SbkEZvEGLNn-2B6FohpNoV33vsNKk-2BltEHyhBHdHmurNCHCJ1LdPOMT5P5bitk3Ph= fOggWSIfr06nTUA3mPMJj6Wb68XFoe1TOHwxCBf2LMmO8G5wT9kgsWzV4V8nbS-2FjIk8rtpElj= miAaHdHV74sZRXYd-2B-2FJGGDuLE-2BQ-2BBdSaB5yW1Y4dim6ViEexaiEfdLTL0P975K8ZCKz= vuB7RwkdIivlzvhYKCpoYYerbE3ttFvuqlMifQGCm-2F-2B0tkNOHnSC3I-3D This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUz= lo7XKIuSly0rC4Oa12rFuiaXNgb0F6L7ybSCidGRlUFwTxzrkzCt6dOMzdZPcjqPbg8jratFLJj= fTg-3D-3DZ3kd_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BI= fez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV= 33vsNKk-2BltEHyhBHdHmurNCHCJ1LdPOMT5P5bitk3PhfOggWSIfr06nTUA3mPMJj6Wb68XFoe= 1TOHwxCBf2LMmOxQma91qZM6GQ-2BKFhAQRzFkUREx0SGNWiSFV4AlnKyQVZIiROfZEMw-2FZvU= 4lmdfghJGMVBKbvbojdfOSh6DVxWFe76YqrEB49mC-2FlJoMFRR7VfhUOUIM5miGtvq-2B332BH= Wfkpz6kJXR87ohIIkxhT6g-3D . For further information, contact UCB:=C2=A0 Investor Relations Antje Witte=C2=A0 T +32 2 559 94 14 antje.witte@ucb.com Corporate Communications Laurent Schots=C2=A0 T+32 2 559 92 64 laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 9,000 peopl= e in approximately 40 countries, the company generated revenue of =E2=82=AC= 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll= ow us on Twitter: @UCB_news. GenericFile 240405 - Acquisition of own shares ENG (https://u7061146.ct.sendgrid.net/ls= /click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepadzxDFtX8-2= FEDs9gF-2F9WS5ul-2BD8VASiKALS4l4YuHbajTbLa-2F8Yzce1BSF3faJvqlo-3DveKa_2dCLU= NbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6= ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33vsNKk-2BltEHyhBHd= HmurNCHCJ1LdPOMT5P5bitk3PhfOggWSIfr06nTUA3mPMJj6Wb68XFoe1TOHwxCBf2LMmO-2BQc= -2FW8KJGFCAV0kswBT6oCn84c69AoDJbsFKYy7DH9Sl8xg0r1G8L6sjB4bX84YdaolqYo6DpF23= NEa5pkpOKowFPa6jCc16iantiDxcWFU9si9tNtvyMt8v98Km3ukhk7WOtWIfDGETgYo9wRGqdU-= 3D GenericFile 240405 - Verwerving van eigen aandelen NL (https://u7061146.ct.sendgrid.net= /ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepadzxDFtX= 8-2FEDs9gF-2F9WS5uqXbzHTedkdDMrInkmruNSn5Q8qb1PHhPFnbHEjPZFxo-3DbFnz_2dCLUN= buBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6Z= opJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33vsNKk-2BltEHyhBHdH= murNCHCJ1LdPOMT5P5bitk3PhfOggWSIfr06nTUA3mPMJj6Wb68XFoe1TOHwxCBf2LMmO-2F8-2= Bd3ETX79bd6WQDpheWMRAajNcKKg3I9mxxI-2BzqDddyrU4jVnhdUqDyqKrSi2BKZPZlGqLLlZa= 8i23JUak5d7ZReZ4JccXk12PTnOLxasgywSSige6Dw1KQO6ffq1U68HwNFXo06w3VhADJ2P924w= -3D GenericFile 240405 - Acquisition actions propres FR (https://u7061146.ct.sendgrid.net/l= s/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepadzxDFtX8-= 2FEDs9gF-2F9WS5u6CV0lUm8h5aHgTKxGFxTAU7-2BXPAqEve0JuHG2TRlNWE-3DuSUl_2dCLUN= buBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6Z= opJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33vsNKk-2BltEHyhBHdH= murNCHCJ1LdPOMT5P5bitk3PhfOggWSIfr06nTUA3mPMJj6Wb68XFoe1TOHwxCBf2LMmO2FKknq= 2Pa-2BwiGcNH0-2BEnYN4ZMDhMaG8QlvArRzq4TC52ZWF4sjq5AOCfif3n3ya8LuDMn-2BW86v7= 903zivCllvV1UNo3YhAX9cPoN01pvrv2M0Ghx2ZwM-2FmRbQei9mB8IsvdpPiIzAeAWqyVhLdF-= 2Fic-3D Image Chart 1 April 5 2024 (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.= gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepadzxDFtX8-2FEDs9gF-2F9WS5uq3D= SmMCyjGDRjVjnAok1xaUyLiVchX-2F7imnxKSwSMGU-3DWSIY_2dCLUNbuBjhX746-2FvM63L9H= yn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO9= 3DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33vsNKk-2BltEHyhBHdHmurNCHCJ1LdPOMT5P5b= itk3PhfOggWSIfr06nTUA3mPMJj6Wb68XFoe1TOHwxCBf2LMmOxqJlo1-2Ba-2B2M0exAIkCbSK= kE0IWCUXrkxtub4WBBOG-2FksbNYkfEEE6dXToDRbT5o9477b5hmuuBi7VoL-2F7ag-2B8Imdph= cZOFn8wxmG3X-2B9MnzsgBOnQ0Lu6NJFI-2F1a6oy4vpthV4io3VEVowe8tfoNtU-3D ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu= Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNWC-2BH92omz75u7fPIvW7nci= keyRtWjXjg-2FjvLmeVQeWVnN0hYtZ5INOQsxHz2pdQvbNP5cJQhRaEPDgY0C0rrIqLTjiv4Tl1= g8DF3TYsc4wk-3DCs2C_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2= nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6F= ohpNoV33vsNKk-2BltEHyhBHdHmurNCHCJ1LdPOMT5P5bitk3PhfOggWSIfr06nTUA3mPMJj6Wb= 68XFoe1TOHwxCBf2LMmO3M5oIvMQ0VljlJ6ltnlby4PP11rMxaQXq48MUCfWbPsP19P65BvKtM7= 73XdiVoTDE110UMRa2mxalUEuvZtPp6OVrU9aGc-2FOob3F6QrefbTBueqXOAofM6v3W-2Fo6Ae= OklmBbnyfB87VCGmwVqH1RiA-3D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium